GB2524552B - Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer - Google Patents

Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer

Info

Publication number
GB2524552B
GB2524552B GB1405475.3A GB201405475A GB2524552B GB 2524552 B GB2524552 B GB 2524552B GB 201405475 A GB201405475 A GB 201405475A GB 2524552 B GB2524552 B GB 2524552B
Authority
GB
United Kingdom
Prior art keywords
gdf
growth
monoclonal antibodies
treating cancer
differentiation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1405475.3A
Other versions
GB2524552A (en
GB201405475D0 (en
Inventor
Wischhusen Jorg
junker Markus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Priority to GB1405475.3A priority Critical patent/GB2524552B/en
Publication of GB201405475D0 publication Critical patent/GB201405475D0/en
Priority to NZ724649A priority patent/NZ724649A/en
Priority to EP23203704.4A priority patent/EP4316596A3/en
Priority to HUE15712629A priority patent/HUE047398T2/en
Priority to ES15712629T priority patent/ES2763859T3/en
Priority to CA2943694A priority patent/CA2943694A1/en
Priority to SI201531059T priority patent/SI3122775T1/en
Priority to FIEP19205321.3T priority patent/FI3653644T3/en
Priority to JP2016559286A priority patent/JP6865585B2/en
Priority to DK15712629.3T priority patent/DK3122775T3/en
Priority to EP19205321.3A priority patent/EP3653644B1/en
Priority to EP15712629.3A priority patent/EP3122775B1/en
Priority to LTEP15712629.3T priority patent/LT3122775T/en
Priority to BR122023027559-4A priority patent/BR122023027559A2/en
Priority to PL15712629T priority patent/PL3122775T3/en
Priority to PT192053213T priority patent/PT3653644T/en
Priority to BR112016022013-7A priority patent/BR112016022013B1/en
Priority to PT157126293T priority patent/PT3122775T/en
Priority to CN201580027932.8A priority patent/CN106536553B/en
Priority to PL19205321.3T priority patent/PL3653644T3/en
Priority to ES19205321T priority patent/ES2965626T3/en
Priority to KR1020167029710A priority patent/KR102520978B1/en
Priority to DK19205321.3T priority patent/DK3653644T5/en
Priority to HRP20231514TT priority patent/HRP20231514T1/en
Priority to US15/128,604 priority patent/US20170204174A1/en
Priority to RS20191652A priority patent/RS59700B1/en
Priority to AU2015238264A priority patent/AU2015238264B2/en
Priority to PCT/EP2015/056654 priority patent/WO2015144855A1/en
Priority to HUE19205321A priority patent/HUE064573T2/en
Priority to LTEP19205321.3T priority patent/LT3653644T/en
Publication of GB2524552A publication Critical patent/GB2524552A/en
Priority to IL248038A priority patent/IL248038B/en
Publication of GB2524552B publication Critical patent/GB2524552B/en
Application granted granted Critical
Priority to US15/912,358 priority patent/US10604565B2/en
Priority to CY20201100008T priority patent/CY1122456T1/en
Priority to HRP20200034TT priority patent/HRP20200034T1/en
Priority to US16/794,401 priority patent/US11634482B2/en
Priority to US16/794,406 priority patent/US11760795B2/en
Priority to IL276405A priority patent/IL276405B/en
Priority to AU2020260440A priority patent/AU2020260440B2/en
Priority to JP2021064572A priority patent/JP2021119138A/en
Priority to JP2023062338A priority patent/JP2023098966A/en
Priority to US18/364,173 priority patent/US20230382987A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GB1405475.3A 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer Active GB2524552B (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
DK19205321.3T DK3653644T5 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) AND USES THEREOF FOR THE TREATMENT OF CANCER-RELATED CACHESIA AND CANCER
CN201580027932.8A CN106536553B (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15(GDF-15) and their use for treating cancer cachexia and cancer
HUE15712629A HUE047398T2 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HRP20231514TT HRP20231514T1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
CA2943694A CA2943694A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
SI201531059T SI3122775T1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
FIEP19205321.3T FI3653644T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
JP2016559286A JP6865585B2 (en) 2014-03-26 2015-03-26 Monoclonal antibody against growth differentiation factor 15 (GDF-15) and its use for treating cancer cachexia and cancer
DK15712629.3T DK3122775T3 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES FOR GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND ITS APPLICATIONS FOR TREATING CANCER KAKEKSI AND CANCER
EP19205321.3A EP3653644B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
EP15712629.3A EP3122775B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
LTEP15712629.3T LT3122775T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
BR122023027559-4A BR122023027559A2 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), CASE COMPRISING THEM, EXPRESSION VECTOR THAT CODES THEM AND CELL LINE CAPABLE OF PRODUCING THEM
PL15712629T PL3122775T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
PT192053213T PT3653644T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
BR112016022013-7A BR112016022013B1 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES BINDING TO HUMAN GDF-15 AND KIT COMPRISING THE SAME
PT157126293T PT3122775T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
RS20191652A RS59700B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
PL19205321.3T PL3653644T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
ES19205321T ES2965626T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies against growth and differentiation factor 15 (GDF-15), and uses thereof to treat cancer cachexia and cancer
KR1020167029710A KR102520978B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
NZ724649A NZ724649A (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
ES15712629T ES2763859T3 (en) 2014-03-26 2015-03-26 Monoclonal Antibodies to Growth and Differentiation Factor 15 (GDF-15), and Uses thereof to Treat Cancer Cachexia and Cancer
US15/128,604 US20170204174A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
EP23203704.4A EP4316596A3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
AU2015238264A AU2015238264B2 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HUE19205321A HUE064573T2 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
LTEP19205321.3T LT3653644T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
IL248038A IL248038B (en) 2014-03-26 2016-09-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
US15/912,358 US10604565B2 (en) 2014-03-26 2018-03-05 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
CY20201100008T CY1122456T1 (en) 2014-03-26 2020-01-08 MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER
HRP20200034TT HRP20200034T1 (en) 2014-03-26 2020-01-09 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
US16/794,406 US11760795B2 (en) 2014-03-26 2020-02-19 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
US16/794,401 US11634482B2 (en) 2014-03-26 2020-02-19 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
IL276405A IL276405B (en) 2014-03-26 2020-07-30 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
AU2020260440A AU2020260440B2 (en) 2014-03-26 2020-10-28 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
JP2021064572A JP2021119138A (en) 2014-03-26 2021-04-06 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
JP2023062338A JP2023098966A (en) 2014-03-26 2023-04-06 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
US18/364,173 US20230382987A1 (en) 2014-03-26 2023-08-02 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and usesthereof for treating cancer cachexia and cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer

Publications (3)

Publication Number Publication Date
GB201405475D0 GB201405475D0 (en) 2014-05-07
GB2524552A GB2524552A (en) 2015-09-30
GB2524552B true GB2524552B (en) 2017-07-12

Family

ID=50686994

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1405475.3A Active GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer

Country Status (1)

Country Link
GB (1) GB2524552B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3084365B1 (en) * 2018-07-27 2020-10-23 Cisbio Bioassays SINGLE DOMAIN ANTIBODIES BOUND WITH G ALPHA PROTEIN

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010010908A1 (en) * 1999-03-25 2001-08-02 Patricia A. Billing-Medel Reagents and methods useful for detecting diseases of the prostate
US20090004181A1 (en) * 2004-04-13 2009-01-01 St Vincent's Hospitalsydney Limited Method for Modulating Appetite
WO2013023557A1 (en) * 2011-08-12 2013-02-21 中国医学科学院肿瘤研究所 Humanized monoclone antibody of macrophage inhibition factor 1 and use thereof
WO2014049087A1 (en) * 2012-09-26 2014-04-03 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010010908A1 (en) * 1999-03-25 2001-08-02 Patricia A. Billing-Medel Reagents and methods useful for detecting diseases of the prostate
US20090004181A1 (en) * 2004-04-13 2009-01-01 St Vincent's Hospitalsydney Limited Method for Modulating Appetite
WO2013023557A1 (en) * 2011-08-12 2013-02-21 中国医学科学院肿瘤研究所 Humanized monoclone antibody of macrophage inhibition factor 1 and use thereof
WO2014049087A1 (en) * 2012-09-26 2014-04-03 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochemistry (2000); Vol 40, pp 65-73, "Epitope mapping of the transforming growth factor-beta...", Fairlie et al *
Cancer Science (Feb 2014); Vol 105, pp 176-185, "Macrophage inhibitory factor 1 acts as a potential biomarker...", Wang et al *
Nature Medicine (2007); Vol 13, pp 1333-1340, "Tumor-induced anorexia and weight loss...", Johnen et al *

Also Published As

Publication number Publication date
GB2524552A (en) 2015-09-30
GB201405475D0 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
IL276405B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HK1245134A1 (en) Treatment of cancer with anti-lap monoclonal antibodies
IL267803A (en) Methods of treating cancer with anti-tim-3 antibodies
IL264674B1 (en) Anti-siglec-7 antibodies for the treatment of cancer
IL248528B (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
IL275092A (en) Methods for treating crohn's disease using an anti-il23 antibody
PT3063173T (en) Specific anti-cd38 antibodies for treating human cancers
IL260474B (en) Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
IL277861A (en) Axl-specific antibodies for cancer treatment
IL250507A0 (en) Anti-ck8 antibodies for use in the treatment of cancers
HK1219232A1 (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment adi-peg 20
SG11201702103XA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
GB2524553B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB201500875D0 (en) Antibodies for treatment and diagnosis
GB2524552B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
ZA201707117B (en) Antibody compositions for tumor treatment